Additional Methods
We collected a total of 421 blood samples from 326 healthy men and women, 18-77 years of age. We categorized participants into 3 study arms: primary vaccination (reference groups), secondary vaccination, and multiple vaccination, on the basis of their status of having had a single dose of 17DD-YF vaccine, secondary (booster) dose, or multiple (>2) vaccination.
We sub-grouped participants according to distinct time-point before or after vaccination. The primary vaccination arm comprises 233 samples collected from 183 healthy adults of both sexes.
The secondary vaccination arm comprises 183 samples collected from 138 healthy adults of both sexes. The multiple vaccination arm comprises 5 samples collected from 5 healthy adults of both sexes.
We analyzed 17DD-YF-specific memory by establishing the phenotypic features of peripheral blood mononuclear cells upon 17DD-YF antigen recall in vitro. We performed flow cytometric immunophenotypic staining to identify distinct T-cell memory subsets, including 
RV(y≥10).
In the comparative analyses between distinct time-points we paid special attention to the set of 3 phenotypic and functional biomarkers considered relevant universal attributes to monitor 17DD-YF specific memory: EMCD4, EMCD8, and IFNCD8. Particular attention was given to We assessed resultant memory by plaque-reducing neutralization test (PRNT) and EMCD8 measurement before and after primary and secondary 17DD-YF vaccination at participant level to calculate the overall proportion of participants for whom test results showed EMCD8 or PRNT levels above the cutoff threshold, i.e., PRNT positivity at serum dilution >1:50 and EMCD8 index above the global median value (17DD-YF Ag/CC Index >1.13). Then, we performed χ 2 tests to determine the resultant memory for each subgroup in the primary vaccination and secondary vaccination study arms. We noted significant differences at p<0.05.
We assessed immune response before and after primary, secondary, or multiple 17DD-YF vaccination, including the levels of 17DD-YF-specific neutralizing antibodies, 17DD-YFspecific phenotypic and functional biomarkers, and resultant memory status.
Page 3 The results are expressed as reverse of serum dilution and seropositivity rates determined considering the serum dilution higher 1:50 as the cutoff criterion for PRNT positivity. Participant subgroups indicate number of days or years since vaccination (in parentheses; d0 for those never vaccinated).
